EZH2 and cancer: Nuclear factor‐kappa B activity is augmented under the action of EZH2, a histone methyltransferase and transcriptional repressor displaying elevated and non‐canonical transactivation activity in several cancers.14, 15, 16, 17 In the canonical pathway, EZH2 acts as the catalytic subunit of the polycomb repressive complex 2 (PRC2) and prevents gene expression by methylating histone H3 on lysine 27.